IMS Health acquires SDG's life sciences practice

Published: 19-Dec-2006
Research & Development

Market intelligence provider to the pharmaceutical and healthcare industries IMS Health is to acquire the Life Sciences practice of Strategic Decisions Group (SDG), the portfolio strategy consultancy to the pharmaceutical and biotech industries.


Market intelligence provider to the pharmaceutical and healthcare industries IMS Health is to acquire the Life Sciences practice of Strategic Decisions Group (SDG), the portfolio strategy consultancy to the pharmaceutical and biotech industries.

Financial terms of the transaction were not disclosed.

'This combination will provide clients with a broader range of services and deeper strategic insights earlier in the product development process,' said Ray Hill, general manager at IMS Global Consulting.

'We look forward to leveraging SDG's unmatched experience and expertise to help our clients go from portfolio strategy to implementation more efficiently and with lower risk,' Hill added.

Headquartered in Palo Alto, California, SDG's Life Sciences practice has consultants located in offices in New York City, Boston, Houston and London. SDG's industry-standard portfolio planning frameworks have transformed the way investment decisions are evaluated and implemented, the company says.

SDG will continue to operate and serve clients in energy and chemicals, technology and financial services, as well as other industries, following the acquisition of its life sciences practice by IMS.

Robin Arnold, ceo of SDG and a leading partner in the life sciences practice, said: 'We are excited about this opportunity to dramatically increase the value of our services to the pharmaceutical industry. By blending SDG's historical strengths with IMS's consulting, forecasting and competitive intelligence, SDG can now deliver real-time market performance insight to support clients' needs across the entire portfolio planning continuum - from r&d through product maturity.'

See more

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Read more
Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator

Trending Articles

  1. Douglas Pharmaceuticals sets new benchmark for capsule quality with CI Precision Partnership delivers compliance confidence, efficiency gains and reduced waste
  2. Servier acquires potential treatment for Fragile X syndrome KER-0193, a novel, orally bioavailable small molecule, was granted orphan drug and rare paediatric drug designation by the US FDA
  3. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  4. Ryvu to support BioNTech’s clinical trials for cancer in Poland Ryvu will leverage its clinical network to streamline access to BioNTech’s investigational immunotherapies for Polish patients
  5. Intranasal GLP-1 medication from Orexo shows positive results in preclinical trial Orexo's AmorphOX technology had positive results when compared against oral and injectable formulations in the study

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Manufacturing

Sapio Sciences introduces world’s first 3rd-generation ELN

Sapio ELaiN is an AI-powered lab notebook designed to act as a scientific collaborator
Research & Development

Genoskin raises $8.7m in its first funding round to advance its ethical, human-based alternatives to animal testing

The financing will drive Genoskin’s next phase of growth, with a view to scaling up operations in both the US and France
Manufacturing

L.B. Bohle to showcase machines for OSD, food and nutraceuticals at PACK EXPO 2025

Company to present advanced blending, particle sizing and coating technologies at Las Vegas event
Drug Delivery

Tiziana receives grant for intranasal anti-CD3 monoclonal antibody therapy for spinal cord injury

The US Department of Defense awarded the biotechnology company a research grant to study the use of intranasal anti-CD3 therapy in traumatic spinal cord injury (SCI)
Regulatory

Novo Nordisk’s oral semaglutide scores EU approval for cardiovascular benefits

Rybelsus is now the first and only oral GLP-1 RA to reduce cardiovascular death, heart attack and stroke
Manufacturing

Anton Paar launches next-generation rheometers for unmatched precision

New instrument series redefines possibilities in rheological testing and analysis
Drug Delivery

Rice University scientists create hydrogel platform for precision, long-lasting drug delivery

The researchers have developed a peptide hydrogel system that slows and extends drug release, improving treatment adherence and efficacy across therapies ranging from tuberculosis medication to insulin
Subscribe now